New drug cocktail shows promise in Hard-to-Treat cancers
NCT ID NCT02159989
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, while ziv-aflibercept cuts off the tumor's blood supply. The study is too small to confirm if the combo works, but it lays groundwork for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sapanisertib and ziv-aflibercept
- What this could lead to
- If it works, this could point toward a new combination treatment for advanced cancers that have stopped responding to standard therapy.
- What could go wrong
- This is a very early Phase I trial with only 83 people, focused on safety and dosing. It is too small to prove effectiveness, and the drugs may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- Can a protein calm the immune System's overreaction to cancer treatment?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a tracer that hunts unstable iron light up hidden tumors?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors